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The question of how best to treat patients with multivessel coronary artery disease and left ven tricular dysfunction has challenged physicians for years. Although most clinicians are comfortable recommending revascularization when there is angina, extensive coronary disease, and a left ven tricular ejection fraction of more than 35%, 1-3 the benefits of such a strategy are less clear when the ejection fraction is substantially impaired.
The evidence base for the benefits of revascu larization is even weaker when angina is not pres ent in patients with ischemic cardiomyopathy. In such a situation, myocardial viability and hiber nation (i.e., chronically hypoperfused myocardi um resulting in a hypocontractile state) provide the rationale for revascularization -namely, that contractile function will improve with ade quate blood flow. Ischemic left ventricular dys function is one of the few truly reversible causes of systolic heart failure. This reversible state has to be clearly distinguished from an irreversibly injured or infarcted ventricle, in which case the restoration of coronary blood flow would not be justified. Numerous nonrandomized clinical stud ies have supported this concept. 4-7 Yet, clinical equipoise exists, since data from randomized, prospective trials have been lacking, and both surgical and nonsurgical therapies for coronary disease and heart failure have improved substan tially. It is in this context that the Surgical Treat ment for Ischemic Heart Failure (STICH) trial, sponsored by the National Heart, Lung, and Blood Institute, was designed and executed.
In this issue of the Journal, two studies -by Velazquez et al. 8 and Bonow et al. 9 -describe the respective findings of the overall STICH trial and of a substudy that was limited to patients who underwent assessment of myocardial viabil ity. In the main study, 1212 patients with an ejec tion fraction of less than 35% and coronary dis ease amenable to coronaryartery bypass grafting (CABG) were randomly assigned to receive opti mal medical therapy for heart failure and coro nary disease (602 patients) or to receive optimal medical therapy plus CABG (610 patients). The original protocol called for the enrollment of 2000 patients who would be followed for 3 years. However, because of slowerthanexpected recruit ment, the study was modified to a target of 1200 patients with 5 years of followup, an en rollment that would still allow a sufficient num ber of events for the trial to be adequately pow ered. The primary end point was death from any cause. Important secondary end points included death from cardiovascular causes and hospital ization.
The results of the main study by Velazquez et al. were illuminating: there was no significant difference in the rate of death from any cause between the two study groups. As expected, there was an early hazard to CABG that abated over 2 years. CABG was effective in significantly re ducing the major secondary end points of the rate of death from cardiovascular causes and the rate of a composite of death or hospitaliza tion for cardiovascular causes. Perhaps surpris ingly, in the substudy by Bonow et al., the inves tigators found that assessment of myocardial viability did not identify patients who might have selectively benefited from CABG.
Before we accept these findings and potential conclusions, what are the strengths and weak nesses of this trial? It was extremely well con ducted. Both surgical and medical oversight com mittees were used to ensure that care with respect to both therapies was optimal. Surgical investi gators were required to show previous surgical expertise (operative mortality, <5%) in patients with ischemic left ventricular dysfunction. More than 90% of the patients who were assigned to the CABG group actually underwent surgery, with a majority of patients undergoing the procedure within the protocolspecified window of 14 days after randomization (median interval, 10 days). Followup was ascertained in more than 99% of patients.
The authors appropriately acknowledge several limitations to the study. Although the crossover rate of 17% was well within the prespecified sta tistical limit (20%), crossovers may have dimin ished the benefits of CABG in the intentionto treat analysis. It should be recognized that clinical equipoise may have also been lost in patients who crossed over, since the reasons for the se lection of CABG in almost half of the cases were at the discretion of the physician, patient, or family. The authors also note that the rele vance of a benefit for CABG with respect to sec ondary end points is uncertain when the pri mary end point was not met. In fact, the clinical relevance of a decrease in cardiovascular mortality is unclear when overall mortality is unaffected. Such was the case in the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), in which the use of implantable cardioverter-defibrilla tors in highrisk patients soon after myocardial infarction did not have a significant effect on the rate of death from any cause, although there was a significant decrease in the rate of sudden cardiac death. 10 Finally, secondary end points that include a subjective outcome such as hospi talization are less robust in an unblinded trial.
Some other observations are worth noting. The trial was a study of ischemic heart disease rather than heart failure per se. The patients were younger (mean age, 60 years) and had more an gina (>60%) and less severe heart failure symp toms (>60% with New York Heart Association functional class I or II) than in a typical group of patients with systolic heart failure. The pres ence of heart failure was not necessary for trial enrollment. In addition, the fate of patients who were screened but did not undergo randomiza tion is not reported. It is possible that these pa tients, particularly those who were considered good surgical candidates, went on to have surgery, thus potentially biasing the randomized study against CABG.
In addition, the results of the substudy of myo cardial viability should be interpreted cautiously. Viability testing was not mandated or performed in a randomized manner but, rather, at the dis cretion of the investigators, which may have intro duced substantial bias. The authors note that there were clinical differences between patients who were tested and those who were not tested. How ever, the substudy's findings do raise reasonable questions about the most appropriate method to assess myocardial viability. Since most of the pa tients had angina, one wonders whether this sim ple question is enough. The analysis is a strong reminder that in this era of costeffectiveness, the role of expensive technologies should be account able to a rigorous study of incremental benefit.
How should these trial results inform our clinical practice? Patients should continue to be evaluated for coronary artery disease when there is left ventricular dysfunction. In the STICH tri al, patients with left main disease or severe an gina were not eligible for randomization. In the absence of these conditions, aggressive medical therapy should be initiated and optimized, accord ing to evidencebased guidelines. Decisions with respect to revascularization (including percuta neous approaches) should be carefully weighed but can be safely deferred as treatment plans are individualized and modified over time. For patients with persistent or progressive symptoms, revascularization can be offered. With the re sults of the STICH trial, we should be comfort able with the notion that in general, surgery is not superior to optimal medical therapy for is chemic left ventricular dysfunction.
Finally, the courage of the patients who con sented to participate in this trial should be ac knowledged. There are few more difficult choices in illness than selecting between two of the most extreme poles of modernday therapeutics. These patients made such a decision on the basis of a coin flip, and none of them lost.
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